Targeting HIV-1 gp41 in close proximity to the membrane using antibody and other molecules

Current Topics in Medicinal Chemistry

Volumn 11, Issue 24, 2011, Pages 2997-3021

  Gach, Johannes S ^a   Leaman, Daniel P ^a   Zwick, Michael B ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

2f5; 4e10; Antibodies; Broadly; Entry inhibitor; Fusion inhibitor; Gp41; HIV; MPER; Neutralizing; Z13e1

Indexed keywords

ANTIBODY; C52L PEPTIDE; ENFUVIRTIDE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIPID BINDING PROTEIN; NEUTRALIZING ANTIBODY; P5 PEPTIDE; TIFUVIRTIDE; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL (TOPIC); CONFORMATION; CRYSTAL STRUCTURE; DRUG POTENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMBRANE PROXIMAL EXTERNAL REGION; NONHUMAN; PROTEIN TARGETING; VIRUS ENVELOPE; X RAY;

AIDS VACCINES; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CELL MEMBRANE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS;

EID: 79959616682     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611798808505     Document Type: Article

References (239)

1. Zwick, M. B. The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring. AIDS, 2005, 19(16), p. 1725-37.
2. Montero, M.; Van Houten, N. E.; Wang, X.; Scott, J. K. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev, 2008, 72(1), p. 54-84.
3. Zwick, M. B.; Labrijn, A. F.; Wang, M.; Spenlehauer, C.; Saphire, E. O.; Binley, J. M.; Moore, J. P.; Stiegler, G.; Katinger, H.; Burton, D. R.; Parren, P. W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol, 2001, 75(22), p. 10892-905.
4. Hessell, A. J.; Rakasz, E. G.; Tehrani, D. M.; Huber, M.; Weisgrau, K. L.; Landucci, G.; Forthal, D. N.; Koff, W. C.; Poignard, P.; Watkins, D. I.; Burton, D. R. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol, 2010, 84(3), p. 1302-13.
5. Nelson, J. D.; Brunel, F. M.; Jensen, R.; Crooks, E. T.; Cardoso, R. M.; Wang, M.; Hessell, A.; Wilson, I. A.; Binley, J. M.; Dawson, P. E.; Burton, D. R.; Zwick, M. B. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J Virol, 2007, 81(8), p. 4033-43.
6. Muster, T.; Steindl, F.; Purtscher, M.; Trkola, A.; Klima, A.; Himmler, G.; Ruker, F.; Katinger, H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol, 1993, 67(11), p. 6642-7.
7. Purtscher, M.; Trkola, A.; Gruber, G.; Buchacher, A.; Predl, R.; Steindl, F.; Tauer, C.; Berger, R.; Barrett, N.; Jungbauer, A.; Et Al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses, 1994, 10(12), p. 1651-8.
8. Salzwedel, K.; West, J. T.; Hunter, E. A conserved tryptophanrich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J Virol, 1999, 73(3), p. 2469-80.
9. Dimitrov, A. S.; Jacobs, A.; Finnegan, C. M.; Stiegler, G.; Katinger, H.; Blumenthal, R. Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry, 2007, 46(5), p. 1398-401.
10. Vishwanathan, S. A.; Hunter, E. Importance of the membrane-perturbing properties of the membrane-proximal external region of human immunodeficiency virus type 1 gp41 to viral fusion. J Virol, 2008, 82(11), p. 5118-26.
11. Frey, G.; Peng, H.; Rits-Volloch, S.; Morelli, M.; Cheng, Y.; Chen, B. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci U S A, 2008, 105(10), p. 3739-44.
12. Follis, K. E.; Larson, S. J.; Lu, M.; Nunberg, J. H. Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state. J Virol, 2002, 76(14), p. 7356-62.
13. De Rosny, E.; Vassell, R.; Jiang, S.; Kunert, R.; Weiss, C. D. Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol, 2004, 78(5), p. 2627-31.
14. Munoz-Barroso, I.; Salzwedel, K.; Hunter, E.; Blumenthal, R. Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol, 1999, 73(7), p. 6089-92.
15. Dimitrov, A. S.; Rawat, S. S.; Jiang, S.; Blumenthal, R. Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion. Biochemistry, 2003, 42(48), p. 14150-8.
16. Schibli, D. J.; Montelaro, R. C.; Vogel, H. J. The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles. Biochemistry, 2001, 40(32), p. 9570-8.
17. Biron, Z.; Khare, S.; Samson, A. O.; Hayek, Y.; Naider, F.; Anglister, J. A monomeric 3(10)-helix is formed in water by a 13-residue peptide representing the neutralizing determinant of HIV-1 on gp41. Biochemistry, 2002, 41(42), p. 12687-96.
18. Barbato, G.; Bianchi, E.; Ingallinella, P.; Hurni, W. H.; Miller, M. D.; Ciliberto, G.; Cortese, R.; Bazzo, R.; Shiver, J. W.; Pessi, A. Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into Its mechanism of neutralization and HIV fusion. J Mol Biol, 2003, 330(5), p. 1101-1115.
19. Ho, J.; Macdonald, K. S.; Barber, B. H. Construction of recombinant targeting immunogens incorporating an HIV-1 neutralizing epitope into sites of differing conformational constraint. Vaccine, 2002, 20(7-8), p. 1169-80.
20. Lawless, M. K.; Barney, S.; Guthrie, K. I.; Bucy, T. B.; Petteway, S. R., Jr.; Merutka, G. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Biochemistry, 1996, 35(42), p. 13697-708.
21. Joyce, J. G.; Hurni, W. M.; Bogusky, M. J.; Garsky, V. M.; Liang, X.; Citron, M. P.; Danzeisen, R. C.; Miller, M. D.; Shiver, J. W.; Keller, P. M. Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J Biol Chem, 2002, 277(48), p. 45811-20.
22. Coutant, J.; Yu, H.; Clement, M. J.; Alfsen, A.; Toma, F.; Curmi, P. A.; Bomsel, M. Both lipid environment and pH are critical for determining physiological solution structure of 3-D-conserved epitopes of the HIV-1 gp41-MPER peptide P1. FASEB J, 2008, 22(12), p. 4338-51.
23. Tulip, P. R.; Gregor, C. R.; Troitzsch, R. Z.; Martyna, G. J.; Cerasoli, E.; Tranter, G.; Crain, J. Conformational plasticity in an HIV-1 antibody epitope. J Phys Chem B, 2010, 114(23), p. 7942-50.
24. Bryson, S.; Ho, J.; Hynes, R. C.; Kunert, R.; Katinger, H.; Klein, M.; Pai, E. F. Cross-Neutralizing Human Monoclonal Anti-HIV-1 Antibody 2F5: Preparation and Crystallographic Analysis of the Free and Epitope-Complexed Forms of its F ab Fragment. Protein and Peptide Letters, 2001, 8(5), p. 413-418.
25. Ofek, G.; Tang, M.; Sambor, A.; Katinger, H.; Mascola, J. R.; Wyatt, R.; Kwong, P. D. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol, 2004, 78(19), p. 10724-37.
26. Davies, D. R.; Cohen, G. H. Interactions of protein antigens with antibodies. Proc Natl Acad Sci U S A, 1996, 93(1), p. 7-12.
27. Binley, J. M.; Wrin, T.; Korber, B.; Zwick, M. B.; Wang, M.; Chappey, C.; Stiegler, G.; Kunert, R.; Zolla-Pazner, S.; Katinger, H.; Petropoulos, C. J.; Burton, D. R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol, 2004, 78(23), p. 13232-52.
28. Walker, L. M.; Phogat, S. K.; Chan-Hui, P. Y.; Wagner, D.; Phung, P.; Goss, J. L.; Wrin, T.; Simek, M. D.; Fling, S.; Mitcham, J. L.; Lehrman, J. K.; Priddy, F. H.; Olsen, O. A.; Frey, S. M.; Hammond, P. W.; Kaminsky, S.; Zamb, T.; Moyle, M.; Koff, W. C.; Poignard, P.; Burton, D. R. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science, 2009, 326(5950), p. 285-9.
29. Corti, D.; Langedijk, J. P.; Hinz, A.; Seaman, M. S.; Vanzetta, F.; Fernandez-Rodriguez, B. M.; Silacci, C.; Pinna, D.; Jarrossay, D.; Balla-Jhagjhoorsingh, S.; Willems, B.; Zekveld, M. J.; Dreja, H.; O'sullivan, E.; Pade, C.; Orkin, C.; Jeffs, S. A.; Montefiori, D. C.; Davis, D.; Weissenhorn, W.; Mcknight, A.; Heeney, J. L.; Sallusto, F.; Sattentau, Q. J.; Weiss, R. A.; Lanzavecchia, A. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One, 2010, 5(1), p. e8805.
30. Wu, X.; Yang, Z. Y.; Li, Y.; Hogerkorp, C. M.; Schief, W. R.; Seaman, M. S.; Zhou, T.; Schmidt, S. D.; Wu, L.; Xu, L.; Longo, N. S.; Mckee, K.; O'dell, S.; Louder, M. K.; Wycuff, D. L.; Feng, Y.; Nason, M.; Doria-Rose, N.; Connors, M.; Kwong, P. D.; Roederer, M.; Wyatt, R. T.; Nabel, G. J.; Mascola, J. R. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science, 2010, 329(5993), p. 856-61.
31. Kunert, R.; Wolbank, S.; Stiegler, G.; Weik, R.; Katinger, H. Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses, 2004, 20(7), p. 755-62.
32. Cardoso, R. M.; Zwick, M. B.; Stanfield, R. L.; Kunert, R.; Binley, J. M.; Katinger, H.; Burton, D. R.; Wilson, I. A. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity, 2005, 22(2), p. 163-73.
33. Cardoso, R. M.; Brunel, F. M.; Ferguson, S.; Zwick, M.; Burton, D. R.; Dawson, P. E.; Wilson, I. A. Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J Mol Biol, 2007, 365(5), p. 1533-44.
34. Brunel, F. M.; Zwick, M. B.; Cardoso, R. M.; Nelson, J. D.; Wilson, I. A.; Burton, D. R.; Dawson, P. E. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J Virol, 2006, 80(4), p. 1680-7.
35. Roux, K. H.; Taylor, K. A. AIDS virus envelope spike structure. Curr Opin Struct Biol, 2007, 17(2), p. 244-52.
36. Zhu, P.; Liu, J.; Bess, J.; Chertova, E.; Lifson, J. D.; Grise, H.; Ofek, G. A.; Taylor, K. A.; Roux, K. H. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature, 2006, 441(7095), p. 847-52.
37. Liu, J.; Bartesaghi, A.; Borgnia, M. J.; Sapiro, G.; Subramaniam, S. Molecular architecture of native HIV-1 gp120 trimers. Nature, 2008, 455(7209), p. 109-13.
38. Zanetti, G.; Briggs, J. A.; Grunewald, K.; Sattentau, Q. J.; Fuller, S. D. Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog, 2006, 2(8), p. e83.
39. Wu, S. R.; Loving, R.; Lindqvist, B.; Hebert, H.; Koeck, P. J.; Sjoberg, M.; Garoff, H. Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure. Proc Natl Acad Sci U S A, 2010, 107(44), p. 18844-9.
40. Pejchal, R.; Gach, J. S.; Brunel, F. M.; Cardoso, R. M.; Stanfield, R. L.; Dawson, P. E.; Burton, D. R.; Zwick, M. B.; Wilson, I. A. A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J Virol, 2009, 83(17), p. 8451-62.
41. Leaman, D. P.; Kinkead, H.; Zwick, M. B. In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1. J Virol, 2010, 84(7), p. 3382-95.
42. Nakamura, K. J.; Gach, J. S.; Jones, L.; Semrau, K.; Walter, J.; Bibollet-Ruche, F.; Decker, J. M.; Heath, L.; Decker, W. D.; Sinkala, M.; Kankasa, C.; Thea, D.; Mullins, J.; Kuhn, L.; Zwick, M. B.; Aldrovandi, G. M. 4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms. PLoS One, 2010, 5(3), p. e9786.
43. Julien, J. P.; Bryson, S.; Nieva, J. L.; Pai, E. F. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. J Mol Biol, 2008, 384(2), p. 377-92.
44. Sun, Z. Y.; Oh, K. J.; Kim, M.; Yu, J.; Brusic, V.; Song, L.; Qiao, Z.; Wang, J. H.; Wagner, G.; Reinherz, E. L. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity, 2008, 28(1), p. 52-63.
45. Song, L.; Sun, Z. Y.; Coleman, K. E.; Zwick, M. B.; Gach, J. S.; Wang, J. H.; Reinherz, E. L.; Wagner, G.; Kim, M. Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface. Proc Natl Acad Sci U S A, 2009, 106(22), p. 9057-62.
46. Liu, J.; Deng, Y.; Dey, A. K.; Moore, J. P.; Lu, M. Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation. Biochemistry, 2009, 48(13), p. 2915-23.
47. Liu, J.; Deng, Y.; Li, Q.; Dey, A. K.; Moore, J. P.; Lu, M. Role of a putative gp41 dimerization domain in human immunodeficiency virus type 1 membrane fusion. J Virol, 2010, 84(1), p. 201-9.
48. [48] Buzon, V.; Natrajan, G.; Schibli, D.; Campelo, F.; Kozlov, M. M.; Weissenhorn, W. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog, 2010, 6(5), p. e1000880.
49. Shi, W.; Bohon, J.; Han, D. P.; Habte, H.; Qin, Y.; Cho, M. W.; Chance, M. R. Structural characterization of HIV gp41 with the membrane-proximal external region. J Biol Chem, 2010, 285(31), p. 24290-8.
50. Blankenship, J. W.; Balambika, R.; Dawson, P. E. Probing backbone hydrogen bonds in the hydrophobic core of GCN4. Biochemistry, 2002, 41(52), p. 15676-84.
51. Subramaniam, S. The SIV surface spike imaged by electron tomography: one leg or three? PLoS Pathog, 2006, 2(8), p. e91.
52. Hammes, G. G.; Chang, Y. C.; Oas, T. G. Conformational selection or induced fit: a flux description of reaction mechanism. Proc Natl Acad Sci U S A, 2009, 106(33), p. 13737-41.
53. Huarte, N.; Lorizate, M.; Maeso, R.; Kunert, R.; Arranz, R.; Valpuesta, J. M.; Nieva, J. L. The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5. J Virol, 2008, 82(18), p. 8986-96.
54. Dennison, S. M.; Stewart, S. M.; Stempel, K. C.; Liao, H. X.; Haynes, B. F.; Alam, S. M. Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions. J Virol, 2009, 83(19), p. 10211-23.
55. Franquelim, H. G.; Chiantia, S.; Veiga, A. S.; Santos, N. C.; Schwille, P.; Castanho, M. A. Anti-HIV-1 antibodies 2F5 and 4E10 interact differently with lipids to bind their epitopes. AIDS, 2011, 25(4), p. 419-28.
56. Veiga, A. S.; Pattenden, L. K.; Fletcher, J. M.; Castanho, M. A.; Aguilar, M. I. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems. Chembiochem, 2009, 10(6), p. 1032-44.
57. Apellaniz, B.; Garcia-Saez, A. J.; Huarte, N.; Kunert, R.; Vorauer-Uhl, K.; Katinger, H.; Schwille, P.; Nieva, J. L. Confocal microscopy of giant vesicles supports the absence of HIV-1 neutralizing 2F5 antibody reactivity to plasma membrane phospholipids. FEBS Lett, 2010, 584(8), p. 1591-6.
58. Cook, G. A.; Zhang, H.; Park, S. H.; Wang, Y.; Opella, S. J. Comparative NMR studies demonstrate profound differences between two viroporins: p7 of HCV and Vpu of HIV-1. Biochim Biophys Acta, 2010.
59. Suarez, T.; Nir, S.; Goni, F. M.; Saez-Cirion, A.; Nieva, J. L. The pre-transmembrane region of the human immunodeficiency virus type-1 glycoprotein: a novel fusogenic sequence. FEBS Lett, 2000, 477(1-2), p. 145-9.
60. Brugger, B.; Glass, B.; Haberkant, P.; Leibrecht, I.; Wieland, F. T.; Krausslich, H. G. The HIV lipidome: a raft with an unusual composition. Proc Natl Acad Sci U S A, 2006, 103(8), p. 2641-6.
61. Stano, P.; Bufali, S.; Domazou, A. S.; Luisi, P. L. Effect of tryptophan oligopeptides on the size distribution of POPC liposomes: a dynamic light scattering and turbidimetric study. J Liposome Res, 2005, 15(1-2), p. 29-47.
62. Apellaniz, B.; Nir, S.; Nieva, J. L. Distinct mechanisms of lipid bilayer perturbation induced by peptides derived from the membrane-proximal external region of HIV-1 gp41. Biochemistry, 2009, 48(23), p. 5320-31.
63. Lorizate, M.; Cruz, A.; Huarte, N.; Kunert, R.; Perez-Gil, J.; Nieva, J. L. Recognition and blocking of HIV-1 gp41 pre-transmembrane sequence by monoclonal 4E10 antibody in a Raft-like membrane environment. J Biol Chem, 2006, 281(51), p. 39598-606.
64. Lorizate, M.; Huarte, N.; Saez-Cirion, A.; Nieva, J. L. Interfacial pre-transmembrane domains in viral proteins promoting membrane fusion and fission. Biochim Biophys Acta, 2008, 1778(7-8), p. 1624-39.
65. Alfsen, A.; Bomsel, M. HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. J Biol Chem, 2002, 277(28), p. 25649-59.
66. Alfsen, A.; Iniguez, P.; Bouguyon, E.; Bomsel, M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J Immunol, 2001, 166(10), p. 6257-65.
67. Saez-Cirion, A.; Nir, S.; Lorizate, M.; Agirre, A.; Cruz, A.; Perez-Gil, J.; Nieva, J. L. Sphingomyelin and cholesterol promote HIV-1 gp41 pretransmembrane sequence surface aggregation and membrane restructuring. J Biol Chem, 2002, 277(24), p. 21776-85.
68. Huarte, N.; Lorizate, M.; Kunert, R.; Nieva, J. L. Lipid modulation of membrane-bound epitope recognition and blocking by HIV-1 neutralizing antibodies. FEBS Lett, 2008, 582(27), p. 3798-804.
69. Veiga, A. S.; Castanho, M. A. The influence of cholesterol on the interaction of HIV gp41 membrane proximal region-derived peptides with lipid bilayers. FEBS J, 2007, 274(19), p. 5096-104.
70. Shnaper, S.; Sackett, K.; Gallo, S. A.; Blumenthal, R.; Shai, Y. The C- and the N-terminal regions of glycoprotein 41 ectodomain fuse membranes enriched and not enriched with cholesterol, respectively. J Biol Chem, 2004, 279(18), p. 18526-34.
71. Xu, X.; London, E. The effect of sterol structure on membrane lipid domains reveals how cholesterol can induce lipid domain formation. Biochemistry, 2000, 39(5), p. 843-9.
72. Kliger, Y.; Gallo, S. A.; Peisajovich, S. G.; Munoz-Barroso, I.; Avkin, S.; Blumenthal, R.; Shai, Y. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. J Biol Chem, 2001, 276(2), p. 1391-7.
73. White, S. H.; Wimley, W. C. Membrane protein folding and stability: physical principles. Annu Rev Biophys Biomol Struct, 1999, 28, p. 319-65.
74. Wimley, W. C.; White, S. H. Experimentally determined hydrophobicity scale for proteins at membrane interfaces. Nat Struct Biol, 1996, 3(10), p. 842-8.
75. Saez-Cirion, A.; Arrondo, J. L.; Gomara, M. J.; Lorizate, M.; Iloro, I.; Melikyan, G.; Nieva, J. L. Structural and functional roles of HIV-1 gp41 pretransmembrane sequence segmentation. Biophys J, 2003, 85(6), p. 3769-80.
76. Campbell, S. M.; Crowe, S. M.; Mak, J. Virion-associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity. AIDS, 2002, 16(17), p. 2253-61.
77. Guyader, M.; Kiyokawa, E.; Abrami, L.; Turelli, P.; Trono, D. Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization. J Virol, 2002, 76(20), p. 10356-64.
78. Liao, Z.; Graham, D. R.; Hildreth, J. E. Lipid rafts and HIV pathogenesis: virion-associated cholesterol is required for fusion and infection of susceptible cells. AIDS Res Hum Retroviruses, 2003, 19(8), p. 675-87.
79. Viard, M.; Parolini, I.; Sargiacomo, M.; Fecchi, K.; Ramoni, C.; Ablan, S.; Ruscetti, F. W.; Wang, J. M.; Blumenthal, R. Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells. J Virol, 2002, 76(22), p. 11584-95.
80. Vincent, N.; Genin, C.; Malvoisin, E. Identification of a conserved domain of the HIV-1 transmembrane protein gp41 which interacts with cholesteryl groups. Biochim Biophys Acta, 2002, 1567(1-2), p. 157-64.
81. Li, H.; Papadopoulos, V. Peripheral-type benzodiazepine receptor function in cholesterol transport. Identification of a putative cholesterol recognition/interaction amino acid sequence and consensus pattern. Endocrinology, 1998, 139(12), p. 4991-7.
82. Epand, R. F.; Thomas, A.; Brasseur, R.; Vishwanathan, S. A.; Hunter, E.; Epand, R. M. Juxtamembrane protein segments that contribute to recruitment of cholesterol into domains. Biochemistry, 2006, 45(19), p. 6105-14.
83. Epand, R. M.; Sayer, B. G.; Epand, R. F. Peptide-induced formation of cholesterol-rich domains. Biochemistry, 2003, 42(49), p. 14677-89.
84. Greenwood, A. I.; Pan, J.; Mills, T. T.; Nagle, J. F.; Epand, R. M.; Tristram-Nagle, S. CRAC motif peptide of the HIV-1 gp41 protein thins SOPC membranes and interacts with cholesterol. Biochim Biophys Acta, 2008, 1778(4), p. 1120-30.
85. Vishwanathan, S. A.; Thomas, A.; Brasseur, R.; Epand, R. F.; Hunter, E.; Epand, R. M. Large changes in the CRAC segment of gp41 of HIV do not destroy fusion activity if the segment interacts with cholesterol. Biochemistry, 2008, 47(45), p. 11869-76.
86. Epand, R. F.; Sayer, B. G.; Epand, R. M. The tryptophan-rich region of HIV gp41 and the promotion of cholesterol-rich domains. Biochemistry, 2005, 44(14), p. 5525-31.
87. Vishwanathan, S. A.; Thomas, A.; Brasseur, R.; Epand, R. F.; Hunter, E.; Epand, R. M. Hydrophobic substitutions in the first residue of the CRAC segment of the gp41 protein of HIV. Biochemistry, 2008, 47(1), p. 124-30.
88. Reeves, J. D.; Gallo, S. A.; Ahmad, N.; Miamidian, J. L.; Harvey, P. E.; Sharron, M.; Pohlmann, S.; Sfakianos, J. N.; Derdeyn, C. A.; Blumenthal, R.; Hunter, E.; Doms, R. W. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A, 2002, 99(25), p. 16249-54.
89. O'rourke, S. M.; Schweighardt, B.; Phung, P.; Fonseca, D. P.; Terry, K.; Wrin, T.; Sinangil, F.; Berman, P. W. Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. J Virol, 2010, 84(21), p. 11200-9.
90. Blish, C. A.; Nguyen, M. A.; Overbaugh, J. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med, 2008, 5(1), p. e9.
91. O'rourke, S. M.; Schweighardt, B.; Scott, W. G.; Wrin, T.; Fonseca, D. P.; Sinangil, F.; Berman, P. W. Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. J Virol, 2009, 83(15), p. 7728-38.
92. Zwick, M. B.; Jensen, R.; Church, S.; Wang, M.; Stiegler, G.; Kunert, R.; Katinger, H.; Burton, D. R. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol, 2005, 79(2), p. 1252-61.
93. Shen, X.; Parks, R. J.; Montefiori, D. C.; Kirchherr, J. L.; Keele, B. F.; Decker, J. M.; Blattner, W. A.; Gao, F.; Weinhold, K. J.; Hicks, C. B.; Greenberg, M. L.; Hahn, B. H.; Shaw, G. M.; Haynes, B. F.; Tomaras, G. D. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol, 2009, 83(8), p. 3617-25.
94. Shen, X.; Dennison, S. M.; Liu, P.; Gao, F.; Jaeger, F.; Montefiori, D. C.; Verkoczy, L.; Haynes, B. F.; Alam, S. M.; Tomaras, G. D. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. Proc Natl Acad Sci U S A, 2010, 107(13), p. 5972-7.
95. Bellamy-Mcintyre, A. K.; Lay, C. S.; Baar, S.; Maerz, A. L.; Talbo, G. H.; Drummer, H. E.; Poumbourios, P. Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion. J Biol Chem, 2007, 282(32), p. 23104-16.
96. Lorizate, M.; Gomara, M. J.; De La Torre, B. G.; Andreu, D.; Nieva, J. L. Membrane-transferring sequences of the HIV-1 Gp41 ectodomain assemble into an immunogenic complex. J Mol Biol, 2006, 360(1), p. 45-55.
97. Lorizate, M.; De La Arada, I.; Huarte, N.; Sanchez-Martinez, S.; De La Torre, B. G.; Andreu, D.; Arrondo, J. L.; Nieva, J. L. Structural analysis and assembly of the HIV-1 Gp41 amino-terminal fusion peptide and the pretransmembrane amphipathic-at-interface sequence. Biochemistry, 2006, 45(48), p. 14337-46.
98. De La Arada, I.; Julien, J. P.; De La Torre, B. G.; Huarte, N.; Andreu, D.; Pai, E. F.; Arrondo, J. L.; Nieva, J. L. Structural constraints imposed by the conserved fusion peptide on the HIV-1 gp41 epitope recognized by the broadly neutralizing antibody 2F5. J Phys Chem B, 2009, 113(41), p. 13626-37.
99. Peisajovich, S. G.; Epand, R. F.; Pritsker, M.; Shai, Y.; Epand, R. M. The polar region consecutive to the HIV fusion peptide participates in membrane fusion. Biochemistry, 2000, 39(7), p. 1826-33.
100. Liu, S.; Lu, H.; Niu, J.; Xu, Y.; Wu, S.; Jiang, S. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem, 2005, 280(12), p. 11259-73.
101. Wexler-Cohen, Y.; Johnson, B. T.; Puri, A.; Blumenthal, R.; Shai, Y. Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178. J Biol Chem, 2006, 281(14), p. 9005-10.
102. Noah, E.; Biron, Z.; Naider, F.; Arshava, B.; Anglister, J. The membrane proximal external region of the HIV-1 envelope glycoprotein gp41 contributes to the stabilization of the six-helix bundle formed with a matching N' peptide. Biochemistry, 2008, 47(26), p. 6782-92.
103. Champagne, K.; Shishido, A.; Root, M. J. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil. J Biol Chem, 2009, 284(6), p. 3619-27.
104. Freed, E. O.; Martin, M. A. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol, 1996, 70(1), p. 341-51.
105. Crooks, E. T.; Jiang, P.; Franti, M.; Wong, S.; Zwick, M. B.; Hoxie, J. A.; Robinson, J. E.; Moore, P. L.; Binley, J. M. Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. Virology, 2008, 377(2), p. 364-78.
106. Dubay, J. W.; Roberts, S. J.; Hahn, B. H.; Hunter, E. Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J Virol, 1992, 66(11), p. 6616-25.
107. Chernomordik, L. V.; Kozlov, M. M. Mechanics of membrane fusion. Nat Struct Mol Biol, 2008, 15(7), p. 675-83.
108. Kuzmin, P. I.; Zimmerberg, J.; Chizmadzhev, Y. A.; Cohen, F. S. A quantitative model for membrane fusion based on low-energy intermediates. Proc Natl Acad Sci U S A, 2001, 98(13), p. 7235-40.
109. Kunert, R.; Ruker, F.; Katinger, H. Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. AIDS Res Hum Retroviruses, 1998, 14(13), p. 1115-28.
110. Zwick, M. B.; Komori, H. K.; Stanfield, R. L.; Church, S.; Wang, M.; Parren, P. W.; Kunert, R.; Katinger, H.; Wilson, I. A.; Burton, D. R. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol, 2004, 78(6), p. 3155-61.
111. Alam, S. M.; Morelli, M.; Dennison, S. M.; Liao, H. X.; Zhang, R.; Xia, S. M.; Rits-Volloch, S.; Sun, L.; Harrison, S. C.; Haynes, B. F.; Chen, B. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A, 2009, 106(48), p. 20234-9.
112. Ofek, G.; Mckee, K.; Yang, Y.; Yang, Z. Y.; Skinner, J.; Guenaga, F. J.; Wyatt, R.; Zwick, M. B.; Nabel, G. J.; Mascola, J. R.; Kwong, P. D. Relationship between Antibody 2F5 Neutralization of HIV-1 and Hydrophobicity of Its Heavy Chain Third Complementarity-Determining Region. J Virol, 2009.
113. Julien, J. P.; Huarte, N.; Maeso, R.; Taneva, S. G.; Cunningham, A.; Nieva, J. L.; Pai, E. F. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding. J Virol, 2010, 84(9), p. 4136-47.
114. Scherer, E. M.; Leaman, D. P.; Zwick, M. B.; Mcmichael, A. J.; Burton, D. R. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc Natl Acad Sci U S A, 2010, 107(4), p. 1529-34.
115. Alam, S. M.; Mcadams, M.; Boren, D.; Rak, M.; Scearce, R. M.; Gao, F.; Camacho, Z. T.; Gewirth, D.; Kelsoe, G.; Chen, P.; Haynes, B. F. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol, 2007, 178(7), p. 4424-35.
116. Xu, H.; Song, L.; Kim, M.; Holmes, M. A.; Kraft, Z.; Sellhorn, G.; Reinherz, E. L.; Stamatatos, L.; Strong, R. K. Interactions Between Lipids And Human Anti-HIV Antibody 4E10 Can Be Reduced Without Ablating Neutralizing Activity. J Virol, 2009.
117. Parren, P. W.; Marx, P. A.; Hessell, A. J.; Luckay, A.; Harouse, J.; Cheng-Mayer, C.; Moore, J. P.; Burton, D. R. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol, 2001, 75(17), p. 8340-7.
118. Veazey, R. S.; Shattock, R. J.; Pope, M.; Kirijan, J. C.; Jones, J.; Hu, Q.; Ketas, T.; Marx, P. A.; Klasse, P. J.; Burton, D. R.; Moore, J. P. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med, 2003, 9(3), p. 343-6.
119. Ferrantelli, F.; Hofmann-Lehmann, R.; Rasmussen, R. A.; Wang, T.; Xu, W.; Li, P. L.; Montefiori, D. C.; Cavacini, L. A.; Katinger, H.; Stiegler, G.; Anderson, D. C.; Mcclure, H. M.; Ruprecht, R. M. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS, 2003, 17(3), p. 301-9.
120. Baba, T. W.; Liska, V.; Hofmann-Lehmann, R.; Vlasak, J.; Xu, W.; Ayehunie, S.; Cavacini, L. A.; Posner, M. R.; Katinger, H.; Stiegler, G.; Bernacky, B. J.; Rizvi, T. A.; Schmidt, R.; Hill, L. R.; Keeling, M. E.; Lu, Y.; Wright, J. E.; Chou, T. C.; Ruprecht, R. M. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med, 2000, 6(2), p. 200-6.
121. Mascola, J. R.; Stiegler, G.; Vancott, T. C.; Katinger, H.; Carpenter, C. B.; Hanson, C. E.; Beary, H.; Hayes, D.; Frankel, S. S.; Birx, D. L.; Lewis, M. G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med, 2000, 6(2), p. 207-10.
122. Mascola, J. R.; Lewis, M. G.; Stiegler, G.; Harris, D.; Vancott, T. C.; Hayes, D.; Louder, M. K.; Brown, C. R.; Sapan, C. V.; Frankel, S. S.; Lu, Y.; Robb, M. L.; Katinger, H.; Birx, D. L. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol, 1999, 73(5), p. 4009-18.
123. Hessell, A. J.; Poignard, P.; Hunter, M.; Hangartner, L.; Tehrani, D. M.; Bleeker, W. K.; Parren, P. W.; Marx, P. A.; Burton, D. R. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med, 2009, 15(8), p. 951-4.
124. Muster, T.; Guinea, R.; Trkola, A.; Purtscher, M.; Klima, A.; Steindl, F.; Palese, P.; Katinger, H. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol, 1994, 68(6), p. 4031-4.
125. Eckhart, L.; Raffelsberger, W.; Ferko, B.; Klima, A.; Purtscher, M.; Katinger, H.; Ruker, F. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J Gen Virol, 1996, 77 (Pt 9), p. 2001-8.
126. Coeffier, E.; Clement, J. M.; Cussac, V.; Khodaei-Boorane, N.; Jehanno, M.; Rojas, M.; Dridi, A.; Latour, M.; El Habib, R.; Barre-Sinoussi, F.; Hofnung, M.; Leclerc, C. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine, 2000, 19(7-8), p. 684-93.
127. Ho, J.; Uger, R. A.; Zwick, M. B.; Luscher, M. A.; Barber, B. H.; Macdonald, K. S. Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response. Vaccine, 2005, 23(13), p. 1559-73.
128. Law, M.; Cardoso, R. M.; Wilson, I. A.; Burton, D. R. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J Virol, 2007, 81(8), p. 4272-85.
129. Kunert, R. E.; Weik, R.; Ferko, B.; Stiegler, G.; Katinger, H. Anti-idiotypic antibody Ab2/3H6 mimics the epitope of the neutralizing anti-HIV-1 monoclonal antibody 2F5. AIDS, 2002, 16(4), p. 667-8.
130. Gach, J. S.; Quendler, H.; Weik, R.; Katinger, H.; Kunert, R. Partial humanization and characterization of an anti-idiotypic antibody against monoclonal antibody 2F5, a potential HIV vaccine? AIDS Res Hum Retroviruses, 2007, 23(11), p. 1405-15.
131. Bryson, S.; Julien, J. P.; Isenman, D. E.; Kunert, R.; Katinger, H.; Pai, E. F. Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6. J Mol Biol, 2008, 382(4), p. 910-9.
132. Bryson, S.; Julien, J. P.; Hynes, R. C.; Pai, E. F. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications. J Virol, 2009, 83(22), p. 11862-75.
133. Gach, J. S.; Quendler, H.; Strobach, S.; Katinger, H.; Kunert, R. Structural analysis and in vivo administration of an anti-idiotypic antibody against mAb 2F5. Mol Immunol, 2008, 45(4), p. 1027-34.
134. Gach, J. S.; Quendler, H.; Ferko, B.; Katinger, H.; Kunert, R. Expression, purification, and in vivo administration of a promising anti-idiotypic HIV-1 vaccine. Mol Biotechnol, 2008, 39(2), p. 119-25.
135. Phogat, S.; Svehla, K.; Tang, M.; Spadaccini, A.; Muller, J.; Mascola, J.; Berkower, I.; Wyatt, R. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology, 2008, 373(1), p. 72-84.
136. Luo, M.; Yuan, F.; Liu, Y.; Jiang, S.; Song, X.; Jiang, P.; Yin, X.; Ding, M.; Deng, H. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment. Vaccine, 2006, 24(4), p. 435-42.
137. Arnold, G. F.; Velasco, P. K.; Holmes, A. K.; Wrin, T.; Geisler, S. C.; Phung, P.; Tian, Y.; Resnick, D. A.; Ma, X.; Mariano, T. M.; Petropoulos, C. J.; Taylor, J. W.; Katinger, H.; Arnold, E. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol, 2009, 83(10), p. 5087-100.
138. Ofek, G.; Guenaga, F. J.; Schief, W. R.; Skinner, J.; Baker, D.; Wyatt, R.; Kwong, P. D. Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A, 2010, 107(42), p. 17880-7.
139. Correia, B. E.; Ban, Y. E.; Holmes, M. A.; Xu, H.; Ellingson, K.; Kraft, Z.; Carrico, C.; Boni, E.; Sather, D. N.; Zenobia, C.; Burke, K. Y.; Bradley-Hewitt, T.; Bruhn-Johannsen, J. F.; Kalyuzhniy, O.; Baker, D.; Strong, R. K.; Stamatatos, L.; Schief, W. R. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure, 2010, 18(9), p. 1116-26.
140. Binley, J. M.; Lybarger, E. A.; Crooks, E. T.; Seaman, M. S.; Gray, E.; Davis, K. L.; Decker, J. M.; Wycuff, D.; Harris, L.; Hawkins, N.; Wood, B.; Nathe, C.; Richman, D.; Tomaras, G. D.; Bibollet-Ruche, F.; Robinson, J. E.; Morris, L.; Shaw, G. M.; Montefiori, D. C.; Mascola, J. R. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol, 2008, 82(23), p. 11651-68.
141. Gray, E. S.; Taylor, N.; Wycuff, D.; Moore, P. L.; Tomaras, G. D.; Wibmer, C. K.; Puren, A.; Decamp, A.; Gilbert, P. B.; Wood, B.; Montefiori, D. C.; Binley, J. M.; Shaw, G. M.; Haynes, B. F.; Mascola, J. R.; Morris, L. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol, 2009, 83(17), p. 8925-37.
142. Gray, E. S.; Madiga, M. C.; Moore, P. L.; Mlisana, K.; Abdool Karim, S. S.; Binley, J. M.; Shaw, G. M.; Mascola, J. R.; Morris, L. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol, 2009, 83(21), p. 11265-74.
143. Walker, L. M.; Simek, M. D.; Priddy, F.; Gach, J. S.; Wagner, D.; Zwick, M. B.; Phogat, S. K.; Poignard, P.; Burton, D. R. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog, 2010, 6(8).
144. Hinz, A.; Schoehn, G.; Quendler, H.; Hulsik, D. L.; Stiegler, G.; Katinger, H.; Seaman, M. S.; Montefiori, D.; Weissenhorn, W. Characterization of a trimeric MPER containing HIV-1 gp41 antigen. Virology, 2009, 390(2), p. 221-7.
145. Matyas, G. R.; Wieczorek, L.; Beck, Z.; Ochsenbauer-Jambor, C.; Kappes, J. C.; Michael, N. L.; Polonis, V. R.; Alving, C. R. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS, 2009, 23(16), p. 2069-77.
146. Lleo, A.; Invernizzi, P.; Gao, B.; Podda, M.; Gershwin, M. E. Definition of human autoimmunity--autoantibodies versus autoimmune disease. Autoimmun Rev, 2010, 9(5), p. A259-66.
147. Haynes, B. F.; Fleming, J.; St Clair, E. W.; Katinger, H.; Stiegler, G.; Kunert, R.; Robinson, J.; Scearce, R. M.; Plonk, K.; Staats, H. F.; Ortel, T. L.; Liao, H. X.; Alam, S. M. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science, 2005, 308(5730), p. 1906-8.
148. Scherer, E. M.; Zwick, M. B.; Teyton, L.; Burton, D. R. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS, 2007, 21(16), p. 2131-9.
149. Vcelar, B.; Stiegler, G.; Wolf, H. M.; Muntean, W.; Leschnik, B.; Mehandru, S.; Markowitz, M.; Armbruster, C.; Kunert, R.; Eibl, M. M.; Katinger, H. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS, 2007, 21(16), p. 2161-70.
150. Verkoczy, L.; Moody, M. A.; Holl, T. M.; Bouton-Verville, H.; Scearce, R. M.; Hutchinson, J.; Alam, S. M.; Kelsoe, G.; Haynes, B. F. Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region. PLoS One, 2009, 4(10), p. e7215.
151. Ivanov, I; Schelonka, R. L.; Zhuang, Y.; Gartland, G. L.; Zemlin, M.; Schroeder, H. W. Development of the expressed Ig CDR-H3 repertoire is marked by focusing of constraints in length, amino acid use, and charge that are first established in early B cell progenitors. J Immunol, 2005, 174(12), p. 7773-80.
152. Malherbe, L.; Mark, L.; Fazilleau, N.; Mcheyzer-Williams, L. J.; Mcheyzer-Williams, M. G. Vaccine adjuvants alter TCR-based selection thresholds. Immunity, 2008, 28(5), p. 698-709.
153. Armbruster, C.; Stiegler, G. M.; Vcelar, B. A.; Jager, W.; Koller, U.; Jilch, R.; Ammann, C. G.; Pruenster, M.; Stoiber, H.; Katinger, H. W. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J Antimicrob Chemother, 2004, 54(5), p. 915-20.
154. Trkola, A.; Purtscher, M.; Muster, T.; Ballaun, C.; Buchacher, A.; Sullivan, N.; Srinivasan, K.; Sodroski, J.; Moore, J. P.; Katinger, H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol, 1996, 70(2), p. 1100-8.
155. Calarese, D. A.; Scanlan, C. N.; Zwick, M. B.; Deechongkit, S.; Mimura, Y.; Kunert, R.; Zhu, P.; Wormald, M. R.; Stanfield, R. L.; Roux, K. H.; Kelly, J. W.; Rudd, P. M.; Dwek, R. A.; Katinger, H.; Burton, D. R.; Wilson, I. A. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science, 2003, 300(5628), p. 2065-71.
156. Gach, J. S.; Furtmuller, P. G.; Quendler, H.; Messner, P.; Wagner, R.; Katinger, H.; Kunert, R. Proline is not uniquely capable of providing the pivot point for domain swapping in 2G12, a broadly neutralizing antibody against HIV-1. J Biol Chem, 2010, 285(2), p. 1122-7.
157. Trkola, A.; Kuster, H.; Rusert, P.; Joos, B.; Fischer, M.; Leemann, C.; Manrique, A.; Huber, M.; Rehr, M.; Oxenius, A.; Weber, R.; Stiegler, G.; Vcelar, B.; Katinger, H.; Aceto, L.; Gunthard, H. F. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med, 2005, 11(6), p. 615-22.
158. Joos, B.; Trkola, A.; Kuster, H.; Aceto, L.; Fischer, M.; Stiegler, G.; Armbruster, C.; Vcelar, B.; Katinger, H.; Gunthard, H. F. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrob Agents Chemother, 2006, 50(5), p. 1773-9.
159. Mehandru, S.; Vcelar, B.; Wrin, T.; Stiegler, G.; Joos, B.; Mohri, H.; Boden, D.; Galovich, J.; Tenner-Racz, K.; Racz, P.; Carrington, M.; Petropoulos, C.; Katinger, H.; Markowitz, M. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol, 2007, 81(20), p. 11016-31.
160. Gray, E. S.; Meyers, T.; Gray, G.; Montefiori, D. C.; Morris, L. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med, 2006, 3(7), p. e255.
161. Gray, E. S.; Moore, P. L.; Bibollet-Ruche, F.; Li, H.; Decker, J. M.; Meyers, T.; Shaw, G. M.; Morris, L. 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. J Virol, 2008, 82(5), p. 2367-75.
162. Manrique, A.; Rusert, P.; Joos, B.; Fischer, M.; Kuster, H.; Leemann, C.; Niederost, B.; Weber, R.; Stiegler, G.; Katinger, H.; Gunthard, H. F.; Trkola, A. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol, 2007, 81(16), p. 8793-808.
163. Matyas, G. R.; Beck, Z.; Karasavvas, N.; Alving, C. R. Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim Biophys Acta, 2009, 1788(3), p. 660-5.
164. Yuste, E.; Sanford, H. B.; Carmody, J.; Bixby, J.; Little, S.; Zwick, M. B.; Greenough, T.; Burton, D. R.; Richman, D. D.; Desrosiers, R. C.; Johnson, W. E. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol, 2006, 80(6), p. 3030-41.
165. Li, Y.; Svehla, K.; Louder, M. K.; Wycuff, D.; Phogat, S.; Tang, M.; Migueles, S. A.; Wu, X.; Phogat, A.; Shaw, G. M.; Connors, M.; Hoxie, J.; Mascola, J. R.; Wyatt, R. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol, 2009, 83(2), p. 1045-59.
166. Hessell, A. J.; Hangartner, L.; Hunter, M.; Havenith, C. E.; Beurskens, F. J.; Bakker, J. M.; Lanigan, C. M.; Landucci, G.; Forthal, D. N.; Parren, P. W.; Marx, P. A.; Burton, D. R. Fc receptor but not complement binding is important in antibody protection against HIV. Nature, 2007, 449(7158), p. 101-4.
167. Johnson, P. R.; Schnepp, B. C.; Connell, M. J.; Rohne, D.; Robinson, S.; Krivulka, G. R.; Lord, C. I.; Zinn, R.; Montefiori, D. C.; Letvin, N. L.; Clark, K. R. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol, 2005, 79(2), p. 955-65.
168. Luo, X. M.; Maarschalk, E.; O'connell, R. M.; Wang, P.; Yang, L.; Baltimore, D. Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood, 2009, 113(7), p. 1422-31.
169. Johnson, P. R.; Schnepp, B. C.; Zhang, J.; Connell, M. J.; Greene, S. M.; Yuste, E.; Desrosiers, R. C.; Clark, K. R. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med, 2009, 15(8), p. 901-6.
170. Steffen, I.; Pohlmann, S. Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins. Curr Pharm Des, 2010, 16(9), p. 1143-58.
171. Giannecchini, S.; Bonci, F.; Pistello, M.; Matteucci, D.; Sichi, O.; Rovero, P.; Bendinelli, M. The membrane-proximal tryptophan-rich region in the transmembrane glycoprotein ectodomain of feline immunodeficiency virus is important for cell entry. Virology, 2004, 320(1), p. 156-66.
172. D'errico, G.; D'ursi, A. M.; Marsh, D. Interaction of a peptide derived from glycoprotein gp36 of feline immunodeficiency virus and its lipoylated analogue with phospholipid membranes. Biochemistry, 2008, 47(19), p. 5317-27.
173. Garg, H.; Fuller, F. J.; Tompkins, W. A. Mechanism of feline immunodeficiency virus envelope glycoprotein-mediated fusion. Virology, 2004, 321(2), p. 274-86.
174. Giannecchini, S.; Di Fenza, A.; D'ursi, A. M.; Matteucci, D.; Rovero, P.; Bendinelli, M. Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein. J Virol, 2003, 77(6), p. 3724-33.
175. Lombardi, S.; Massi, C.; Indino, E.; La Rosa, C.; Mazzetti, P.; Falcone, M. L.; Rovero, P.; Fissi, A.; Pieroni, O.; Bandecchi, P.; Esposito, F.; Tozzini, F.; Bendinelli, M.; Garzelli, C. Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides. Virology, 1996, 220(2), p. 274-84.
176. D'errico, G.; Vitiello, G.; D'ursi, A. M.; Marsh, D. Interaction of short modified peptides deriving from glycoprotein gp36 of feline immunodeficiency virus with phospholipid membranes. Eur Biophys J, 2009, 38(7), p. 873-82.
177. D'ursi, A. M.; Giannecchini, S.; Di Fenza, A.; Esposito, C.; Armenante, M. R.; Carotenuto, A.; Bendinelli, M.; Rovero, P. Retroinverso analogue of the antiviral octapeptide C8 inhibits feline immunodeficiency virus in serum. J Med Chem, 2003, 46(10), p. 1807-10.
178. Giannecchini, S.; Alcaro, M. C.; Isola, P.; Sichi, O.; Pistello, M.; Papini, A. M.; Rovero, P.; Bendinelli, M. Feline immunodeficiency virus plasma load reduction by a retroinverso octapeptide reproducing the Trp-rich motif of the transmembrane glycoprotein. Antivir Ther, 2005, 10(5), p. 671-80.
179. Sainz, B., Jr.; Mossel, E. C.; Gallaher, W. R.; Wimley, W. C.; Peters, C. J.; Wilson, R. B.; Garry, R. F. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. Virus Res, 2006, 120(1-2), p. 146-55.
180. Galdiero, S.; Falanga, A.; Vitiello, M.; D'isanto, M.; Collins, C.; Orrei, V.; Browne, H.; Pedone, C.; Galdiero, M. Evidence for a role of the membrane-proximal region of herpes simplex virus Type 1 glycoprotein H in membrane fusion and virus inhibition. Chembiochem, 2007, 8(8), p. 885-95.
181. Klein, J. S.; Gnanapragasam, P. N.; Galimidi, R. P.; Foglesong, C. P.; West, A. P., Jr.; Bjorkman, P. J. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc Natl Acad Sci U S A, 2009, 106(18), p. 7385-90.
182. Jiang, S.; Lin, K.; Strick, N.; Neurath, A. R. HIV-1 inhibition by a peptide. Nature, 1993, 365(6442), p. 113.
183. Wild, C. T.; Shugars, D. C.; Greenwell, T. K.; Mcdanal, C. B.; Matthews, T. J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A, 1994, 91(21), p. 9770-4.
184. Zwick, M. B.; Saphire, E. O.; Burton, D. R. gp41: HIV's shy protein. Nat Med, 2004, 10(2), p. 133-4.
185. Weissenhorn, W.; Dessen, A.; Harrison, S. C.; Skehel, J. J.; Wiley, D. C. Atomic structure of the ectodomain from HIV-1 gp41. Nature, 1997, 387(6631), p. 426-30.
186. Chan, D. C.; Fass, D.; Berger, J. M.; Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell, 1997, 89(2), p. 263-73.
187. Chan, D. C.; Kim, P. S. HIV entry and its inhibition. Cell, 1998, 93(5), p. 681-4.
188. [188] Pan, C.; Liu, S.; Jiang, S. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics. J Formos Med Assoc, 109(2), p. 94-105.
189. Naider, F.; Anglister, J. Peptides in the treatment of AIDS. Curr Opin Struct Biol, 2009, 19(4), p. 473-82.
190. Cai, L.; Jiang, S. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41. ChemMedChem, 2010, 5(11), p. 1813-24.
191. Kilby, J. M.; Eron, J. J. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med, 2003, 348(22), p. 2228-38.
192. Kilby, J. M.; Lalezari, J. P.; Eron, J. J.; Carlson, M.; Cohen, C.; Arduino, R. C.; Goodgame, J. C.; Gallant, J. E.; Volberding, P.; Murphy, R. L.; Valentine, F.; Saag, M. S.; Nelson, E. L.; Sista, P. R.; Dusek, A. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses, 2002, 18(10), p. 685-93.
193. Wei, X.; Decker, J. M.; Liu, H.; Zhang, Z.; Arani, R. B.; Kilby, J. M.; Saag, M. S.; Wu, X.; Shaw, G. M.; Kappes, J. C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother, 2002, 46(6), p. 1896-905.
194. Lu, J.; Deeks, S. G.; Hoh, R.; Beatty, G.; Kuritzkes, B. A.; Martin, J. N.; Kuritzkes, D. R. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr, 2006, 43(1), p. 60-4.
195. Eron, J. J.; Gulick, R. M.; Bartlett, J. A.; Merigan, T.; Arduino, R.; Kilby, J. M.; Yangco, B.; Diers, A.; Drobnes, C.; Demasi, R.; Greenberg, M.; Melby, T.; Raskino, C.; Rusnak, P.; Zhang, Y.; Spence, R.; Miralles, G. D. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J Infect Dis, 2004, 189(6), p. 1075-83.
196. Rimsky, L. T.; Shugars, D. C.; Matthews, T. J. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol, 1998, 72(2), p. 986-93.
197. Chan, D. C.; Chutkowski, C. T.; Kim, P. S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A, 1998, 95(26), p. 15613-7.
198. Wexler-Cohen, Y.; Shai, Y. Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. Faseb J, 2007, 21(13), p. 3677-84.
199. Qi, Z.; Shi, W.; Xue, N.; Pan, C.; Jing, W.; Liu, K.; Jiang, S. Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors. J Biol Chem, 2008, 283(44), p. 30376-84.
200. Liu, S.; Jing, W.; Cheung, B.; Lu, H.; Sun, J.; Yan, X.; Niu, J.; Farmar, J.; Wu, S.; Jiang, S. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J Biol Chem, 2007, 282(13), p. 9612-20.
201. Veiga, S.; Henriques, S.; Santos, N. C.; Castanho, M. Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level. Biochem J, 2004, 377(Pt 1), p. 107-10.
202. Peisajovich, S. G.; Gallo, S. A.; Blumenthal, R.; Shai, Y. C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIMIAN immunodeficiency virus-induced membrane fusion. J Biol Chem, 2003, 278(23), p. 21012-7.
203. Hildinger, M.; Dittmar, M. T.; Schult-Dietrich, P.; Fehse, B.; Schnierle, B. S.; Thaler, S.; Stiegler, G.; Welker, R.; Von Laer, D. Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol, 2001, 75(6), p. 3038-42.
204. Egelhofer, M.; Brandenburg, G.; Martinius, H.; Schult-Dietrich, P.; Melikyan, G.; Kunert, R.; Baum, C.; Choi, I.; Alexandrov, A.; Von Laer, D. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol, 2004, 78(2), p. 568-75.
205. Lay, C. S.; Wilson, K. A.; Kobe, B.; Kemp, B. E.; Drummer, H. E.; Poumbourios, P. Expression and biochemical analysis of the entire HIV-2 gp41 ectodomain: determinants of stability map to N- and C-terminal sequences outside the 6-helix bundle core. FEBS Lett, 2004, 567(2-3), p. 183-8.
206. Root, M. J.; Kay, M. S.; Kim, P. S. Protein design of an HIV-1 entry inhibitor. Science, 2001, 291(5505), p. 884-8.
207. Melikyan, G. B.; Egelhofer, M.; Von Laer, D. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion. J Virol, 2006, 80(7), p. 3249-58.
208. Lalezari, J. P.; Bellos, N. C.; Sathasivam, K.; Richmond, G. J.; Cohen, C. J.; Myers, R. A., Jr.; Henry, D. H.; Raskino, C.; Melby, T.; Murchison, H.; Zhang, Y.; Spence, R.; Greenberg, M. L.; Demasi, R. A.; Miralles, G. D. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. J Infect Dis, 2005, 191(7), p. 1155-63.
209. Veiga, A. S.; Santos, N. C.; Loura, L. M.; Fedorov, A.; Castanho, M. A. HIV fusion inhibitor peptide T-1249 is able to insert or adsorb to lipidic bilayers. Putative correlation with improved efficiency. J Am Chem Soc, 2004, 126(45), p. 14758-63.
210. Matos, P. M.; Castanho, M. A.; Santos, N. C. HIV-1 fusion inhibitor peptides enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranes. PLoS One, 2010, 5(3), p. e9830.
211. Martin-Carbonero, L. Discontinuation of the clinical development of fusion inhibitor T-1249. AIDS Rev, 2004, 6(1), p. 61.
212. Deng, Y.; Zheng, Q.; Ketas, T. J.; Moore, J. P.; Lu, M. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Biochemistry, 2007, 46(14), p. 4360-9.
213. Veazey, R. S.; Klasse, P. J.; Schader, S. M.; Hu, Q.; Ketas, T. J.; Lu, M.; Marx, P. A.; Dufour, J.; Colonno, R. J.; Shattock, R. J.; Springer, M. S.; Moore, J. P. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature, 2005, 438(7064), p. 99-102.
214. Yu, H.; Tudor, D.; Alfsen, A.; Labrosse, B.; Clavel, F.; Bomsel, M. Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection. Retrovirology, 2008, 5, p. 93.
215. Otaka, A.; Nakamura, M.; Nameki, D.; Kodama, E.; Uchiyama, S.; Nakamura, S.; Nakano, H.; Tamamura, H.; Kobayashi, Y.; Matsuoka, M.; Fujii, N. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew Chem Int Ed Engl, 2002, 41(16), p. 2937-40.
216. Naito, T.; Izumi, K.; Kodama, E.; Sakagami, Y.; Kajiwara, K.; Nishikawa, H.; Watanabe, K.; Sarafianos, S. G.; Oishi, S.; Fujii, N.; Matsuoka, M. SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob Agents Chemother, 2009, 53(3), p. 1013-8.
217. Jin, B. S.; Ryu, J. R.; Ahn, K.; Yu, Y. G. Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses, 2000, 16(17), p. 1797-804.
218. Dwyer, J. J.; Wilson, K. L.; Davison, D. K.; Freel, S. A.; Seedorff, J. E.; Wring, S. A.; Tvermoes, N. A.; Matthews, T. J.; Greenberg, M. L.; Delmedico, M. K. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci U S A, 2007, 104(31), p. 12772-7.
219. Sia, S. K.; Carr, P. A.; Cochran, A. G.; Malashkevich, V. N.; Kim, P. S. Short constrained peptides that inhibit HIV-1 entry. Proc Natl Acad Sci U S A, 2002, 99(23), p. 14664-9.
220. Ingale, S.; Gach, J. S.; Zwick, M. B.; Dawson, P. E. Synthesis and analysis of the membrane proximal external region epitopes of HIV-1. J Pept Sci, 2010, 16(12), p. 716-22.
221. Ingallinella, P.; Bianchi, E.; Ladwa, N. A.; Wang, Y. J.; Hrin, R.; Veneziano, M.; Bonelli, F.; Ketas, T. J.; Moore, J. P.; Miller, M. D.; Pessi, A. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U S A, 2009, 106(14), p. 5801-6.
222. Zhang, H.; Schneider, S. E.; Bray, B. L.; Friedrich, P. E.; Tvermoes, N. A.; Mader, C. J.; Whight, S. R.; Niemi, T. E.; Silinski, P.; Picking, T.; Warren, M.; Wring, S. A. Process Development of TRI-999, a Fatty-Acid-Modified HIV Fusion Inhibitory Peptide. Organic Process Research & Development, 2007, 12(1), p. 101-110.
223. Esposito, C.; D'errico, G.; Armenante, M. R.; Giannecchini, S.; Bendinelli, M.; Rovero, P.; D'ursi, A. M. Physicochemical characterization of a peptide deriving from the glycoprotein gp36 of the feline immunodeficiency virus and its lipoylated analogue in micellar systems. Biochim Biophys Acta, 2006, 1758(10), p. 1653-61.
224. D'ursi, A. M.; Giannecchini, S.; Esposito, C.; Alcaro, M. C.; Sichi, O.; Armenante, M. R.; Carotenuto, A.; Papini, A. M.; Bendinelli, M.; Rovero, P. Development of antiviral fusion inhibitors: short modified peptides derived from the transmembrane glycoprotein of feline immunodeficiency virus. Chembiochem, 2006, 7(5), p. 774-9.
225. Horne, W. S.; Johnson, L. M.; Ketas, T. J.; Klasse, P. J.; Lu, M.; Moore, J. P.; Gellman, S. H. Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers. Proc Natl Acad Sci U S A, 2009, 106(35), p. 14751-6.
226. Eckert, D. M.; Malashkevich, V. N.; Hong, L. H.; Carr, P. A.; Kim, P. S. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell, 1999, 99(1), p. 103-15.
227. Welch, B. D.; Vandemark, A. P.; Heroux, A.; Hill, C. P.; Kay, M. S. Potent D-peptide inhibitors of HIV-1 entry. Proc Natl Acad Sci U S A, 2007, 104(43), p. 16828-33.
228. Huet, T.; Kerbarh, O.; Schols, D.; Clayette, P.; Gauchet, C.; Dubreucq, G.; Vincent, L.; Bompais, H.; Mazinghien, R.; Querolle, O.; Salvador, A.; Lemoine, J.; Lucidi, B.; Balzarini, J.; Petitou, M. Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother, 2010, 54(1), p. 134-42.
229. Stoddart, C. A.; Nault, G.; Galkina, S. A.; Thibaudeau, K.; Bakis, P.; Bousquet-Gagnon, N.; Robitaille, M.; Bellomo, M.; Paradis, V.; Liscourt, P.; Lobach, A.; Rivard, M. E.; Ptak, R. G.; Mankowski, M. K.; Bridon, D.; Quraishi, O. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J Biol Chem, 2008, 283(49), p. 34045-52.
230. Eckert, D. M.; Shi, Y.; Kim, S.; Welch, B. D.; Kang, E.; Poff, E. S.; Kay, M. S. Characterization of the steric defense of the HIV-1 gp41 N-trimer region. Protein Sci, 2008, 17(12), p. 2091-100.
231. Munch, J.; Standker, L.; Adermann, K.; Schulz, A.; Schindler, M.; Chinnadurai, R.; Pohlmann, S.; Chaipan, C.; Biet, T.; Peters, T.; Meyer, B.; Wilhelm, D.; Lu, H.; Jing, W.; Jiang, S.; Forssmann, W. G.; Kirchhoff, F. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell, 2007, 129(2), p. 263-75.
232. Kim, S.; Pang, H. B.; Kay, M. S. Peptide mimic of the HIV envelope gp120-gp41 interface. J Mol Biol, 2008, 376(3), p. 786-97.
233. Murray, E. J.; Leaman, D. P.; Pawa, N.; Perkins, H.; Pickford, C.; Perros, M.; Zwick, M. B.; Butler, S. L. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41. J Virol, 2010, 84(14), p. 7288-99.
234. Lee, S. J.; Garza, L.; Yao, J.; Notkins, A. L.; Zhou, P. A nonneutralizing anti-HIV-1 antibody turns into a neutralizing antibody when expressed on the surface of HIV-1-susceptible cells: a new way to fight HIV. J Immunol, 2004, 173(7), p. 4618-26.
235. Perez, L. G.; Costa, M. R.; Todd, C. A.; Haynes, B. F.; Montefiori, D. C. Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41. J Virol, 2009, 83(15), p. 7397-410.
236. Davis, K. L.; Bibollet-Ruche, F.; Li, H.; Decker, J. M.; Kutsch, O.; Morris, L.; Salomon, A.; Pinter, A.; Hoxie, J. A.; Hahn, B. H.; Kwong, P. D.; Shaw, G. M. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol, 2009, 83(3), p. 1240-59.
237. Mills, J. S. Peptides derived from HIV-1, HIV-2, Ebola virus, SARS coronavirus and coronavirus 229E exhibit high affinity binding to the formyl peptide receptor. Biochim Biophys Acta, 2006, 1762(7), p. 693-703.
238. Jeetendra, E.; Ghosh, K.; Odell, D.; Li, J.; Ghosh, H. P.; Whitt, M. A. The membrane-proximal region of vesicular stomatitis virus glycoprotein G ectodomain is critical for fusion and virus infectivity. J Virol, 2003, 77(23), p. 12807-18.
239. Schief, W. R.; Ban, Y. E.; Stamatatos, L. Challenges for structure-based HIV vaccine design. Curr Opin HIV AIDS, 2009, 4(5), p. 431-40.